Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMP013 + ALFQ
- Development stage
- Unknown
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
FMP013 + ALFQ is an investigational malaria vaccine candidate developed by the Walter Reed Army Institute of Research (WRAIR). It combines FMP013, a soluble, nearly full-length recombinant Plasmodium falciparum circumsporozoite protein (CSP) antigen expressed in Escherichia coli, with ALFQ (Army Liposome Formulation containing QS-21), a potent liposomal adjuvant containing synthetic monophosphoryl lipid A (3D-PHAD) and QS-21. The vaccine is designed to elicit robust humoral and cellular immune responses against the CSP of Plasmodium falciparum, aiming to prevent sporozoite invasion of the liver and provide sterile protection against malaria. It has been evaluated in Phase I clinical trials using a controlled human malaria infection (CHMI) model.
- Other names
- Falciparum Malaria Protein-013 + ALFQFalciparum Malaria Vaccine-013 + ALFQPlasmodium falciparum Malaria Protein 013 + ALFQ
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on FMP013 + ALFQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMP013 + ALFQ.